Quantcast

Singulex Adds Interleuken – 17A/F Assay to Powerful Suite of TH17 Pathway Immunoassay Kits

May 1, 2012

NYU Study Indicates New Assay Can Further Stratify Autoimmune Inflammatory Disease to Aid in Determining Drug Efficacy

Alameda, Calif. (PRWEB) May 01, 2012

Singulex, Inc., a pioneer and leader in ultra-sensitive, digital biomarker assay platform technology, today announced the launch of its new Erenna® Interleuken-17A/F (IL-17A/F) heterodimer immunoassay kit for the life sciences research community. The new IL-17A/F heterodimer kit is a significant addition to the company´s growing suite of powerful TH17 pathway bioassays which also includes IL-17A and IL-17F as well as several others. These biomarkers are key members of the IL-17 signaling pathway, serving to induce and mediate pro-inflammatory responses in numerous immune mediated diseases.

     Because of the role the biomarkers have in immune-mediated disorders, these cytokines (small cell-signaling molecules) have become a major area of focus in therapeutic drug development and disease stratification. A study at New York University (NYU) Hospital performed a multi-marker analysis of rheumatoid arthritis (RA) versus knee osteoarthritis (OA) patients using the Singulex technology.

         “In rheumatoid arthritis, clinical researchers have believed that IL-17A concentrations were modulated with therapeutic intervention,” said Jeffrey Greenberg, MD, associate director, Clinical and Translational Sciences, Division of Rheumatology, NYU. “However, due to the low naturally occurring concentrations of IL-17A, to date it has been challenging to accurately measure this biomarker. With the Singulex technology, we demonstrated that plasma levels of IL-17F, not IL-17A, were consistently reduced by three efficacious drug classes, suggesting that inhibiting IL-17F may relate to RA drug efficacy,”

     In the NYU study, plasma levels of IL-17A, IL-17F and IL-17A/F were all significantly elevated in RA versus OA patients, but the magnitude of differences varied with IL-17F showing an approximately 18-fold higher concentration in RA versus OA. “These discoveries have important implications around our understanding of the biological pathways that drive RA and OA disease processes and could prove important in the design and clinical development of therapeutic agents to treat these significant diseases,” Greenberg concluded.

     IL-17A, IL-17F and IL-17A/F are thought to play a key role in inflammation, allergic responses and autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, Crohn´s disease, asthma and multiple sclerosis. The Singulex IL-17 immunoassays, optimized for use on the Erenna Immunoassay System, provide the sensitivity to detect very low levels of these biomarkers in blood plasma samples, including those from healthy patients without disease, and allow for the measurement of small changes in their concentrations that can provide insights into drug efficacy or disease progression research.

     “The proprietary digital foundation of the Singulex Erenna Immunoassay platform enables detection of cytokines at the single molecule level,” said Steven Blakely, director of marketing for Singulex. “The extreme sensitivity of the Singulex immunoassay kits has allowed for the robust quantification of IL-17A and IL-17F. The recent addition of IL-17A/F heterodimer has opened up new opportunities for inflammatory disease research by providing information that could not be obtained by any other method.”

About Singulex, Inc.

Singulex, Inc. is a pioneer and leader in developing a proprietary digital technology platform that can quantitatively detect single molecules in complex biological samples. The company´s extensive array of ultra-sensitive assays offers significantly added value for early disease detection, personalized treatment and chronic disease management. This proprietary digital technology has enabled advanced cardiovascular disease testing in support of earlier detection and treatment as well as ongoing monitoring through a simple blood test. The company´s Erenna® Immunoassay System extends the dynamic range of immunoassays by orders of magnitude, allowing drug developers to use biomarkers to measure drug efficacy, safety and disease progression. In addition, the company offers industry-leading sample analysis and assay development services. For further information, visit http://www.singulex.com.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9459920.htm


Source: prweb



comments powered by Disqus